|
1
|
Powles TJ: Breast cancer prevention.
Oncologist. 7:60–64. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nathanson KN, Wooster R and Weber BL:
Breast cancer genetics: what we know and what we need. Nat Med.
7:552–556. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wemer RS, McCormick B, Petrec J, et al:
Arm edema in conservatively managed breast cancer: obesity is a
major predictive factor. Radiology. 180:177–184. 1991. View Article : Google Scholar
|
|
5
|
Clapp RW, Jacobs MM and Loechler EL:
Environmental and occupational causes of cancer: new evidence
2005–2007. Rev Environ Health. 23:1–37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mohankumar K, Pajaniradje S, Sridharan S,
et al: Mechanism of apoptotic induction in human breast cancer
cell, MCF-7, by an analog of curcumin in comparison with curcumin -
an in vitro and in silico approach. Chem Biol Interact. 210:51–63.
2014. View Article : Google Scholar
|
|
7
|
World Health Organization: World cancer
report 2008. Boyle P and Levin B: IARC; 2008
|
|
8
|
Price JT, Tiganis T, Agarwal A, Djakiew D
and Thompson EW: Epidermal growth factor promotes MDA-MB-231 breast
cancer cell migration through a phosphatidylinositol 3′-kinase and
phospholipase C-dependent mechanism. Cancer Res. 59:5475–5478.
1999.PubMed/NCBI
|
|
9
|
Dang TT and Pearson GW: Abstract A38:
Breast cancer intrinsic subtype specific interactions with the
microenvironment dictate the mechanism of tumor invasion. Cancer
Res. 73(3 Supplement): A38. 2013. View Article : Google Scholar
|
|
10
|
Wu K, Weng Z, Tao Q, et al: Stage-specific
expression of breast cancer-specific gene γ-synuclein. Cancer
Epidemiol Biomarkers Prev. 12:920–925. 2003.PubMed/NCBI
|
|
11
|
Shou J, Massarweh S, Osborne CK, et al:
Mechanisms of tamoxifen resistance: increased estrogen
receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J
Natl Cancer Inst. 96:926–935. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pietras RJ, Arboleda J, Reese DM, et al:
HER-2 tyrosine kinase pathway targets estrogen receptor and
promotes hormone-independent growth in human breast cancer cells.
Oncogene. 10:2435–2446. 1995.PubMed/NCBI
|
|
13
|
Kubo M, Nakamura M, Tasaki A, et al:
Hedgehog signaling pathway is a new therapeutic target for patients
with breast cancer. Cancer Res. 64:6071–6074. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Planche A, Bacac M, Provero P, et al:
Identification of prognostic molecular features in the reactive
stroma of human breast and prostate cancer. PLoS One. 6:e186402011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Irizarry RA, Hobbs B, Collin F, et al:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Smyth GK: Linear models and empirical
bayes methods for assessing differential expression in microarray
experiments. Stat Appl Genet Mol Biol. 3:Article3. 2004.
|
|
17
|
Ashburner M, Ball CA, Blake JA, et al:
Gene ontology: tool for the unification of biology. Nat Genet.
25:25–29. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Altermann E and Klaenhammer TR:
PathwayVoyager: pathway mapping using the kyoto encyclopedia of
genes and genomes (KEGG) database. BMC Genomics. 6:602005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Szklarczyk D, Franceschini A, Kuhn M, et
al: The STR ING database in 2011: functional interaction networks
of proteins, globally integrated and scored. Nucleic Acids Res.
39:D561–D568. 2011. View Article : Google Scholar
|
|
20
|
Kohl M, Wiese S and Warscheid B:
Cytoscape: software for visualization and analysis of biological
networks. Methods Mol Biol. 696:291–303. 2011.
|
|
21
|
Bader GD and Hogue CW: An automated method
for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van ’t Veer LJ, Dai H, van de Vijver MJ,
et al: Gene expression profiling predicts clinical outcome of
breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar
|
|
23
|
Wang Y, Klijn JG, Zhang Y, et al:
Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet. 365:671–679.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gumbiner BM: Cell adhesion: The molecular
basis of tissue architecture and morphogenesis. Cell. 84:345–357.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Albelda SM and Buck CA: Integrins and
other cell adhesion molecules. FASEB J. 4:2868–2880.
1990.PubMed/NCBI
|
|
26
|
Albelda S: Role of integrins and other
cell adhesion molecules in tumor progression and metastasis. Lab
Invest. 68:4–17. 1993.PubMed/NCBI
|
|
27
|
Siitonen SM, Kononen JT, Helin HJ, Rantala
IS, Holli KA and Isola JJ: Reduced E-cadherin expression is
associated with invasiveness and unfavorable prognosis in breast
cancer. Am J Clin Pathol. 105:394–402. 1996.PubMed/NCBI
|
|
28
|
Oka H, Shiozaki H, Kobayashi K, et al:
Expression of E-cadherin cell adhesion molecules in human breast
cancer tissues and its relationship to metastasis. Cancer Res.
53:1696–1701. 1993.PubMed/NCBI
|
|
29
|
Saadatmand S, De Kruijf E, Sajet A, et al:
Expression of cell adhesion molecules and prognosis in breast
cancer. Br J Surg. 100:252–260. 2013. View
Article : Google Scholar
|
|
30
|
Springer TA: Adhesion receptors of the
immune system. Nature. 346:425–434. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pankov R and Yamada KM: Fibronectin at a
glance. J Cell Sci. 115:3861–3863. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Steffens S, Schrader A, Vetter G, et al:
Fibronectin 1 protein expression in clear cell renal cell
carcinoma. Oncol Lett. 3:787–790. 2012.PubMed/NCBI
|
|
33
|
Kondo N, Toyama T, Sugiura H, Fujii Y and
Yamashita H: miR-206 expression is down-regulated in estrogen
receptor alpha-positive human breast cancer. Cancer Res.
68:5004–5008. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Adams BD, Claffey KP and White BA:
Argonaute-2 expression is regulated by epidermal growth factor
receptor and mitogen-activated protein kinase signaling and
correlates with a transformed phenotype in breast cancer cells.
Endocrinology. 150:14–23. 2009. View Article : Google Scholar :
|
|
35
|
Mutlu P, Ural AU and Gunduz U:
Differential gene expression analysis related to extracellular
matrix components in drug-resistant RPMI-8226 cell line. Biomed
Pharmacother. 66:228–231. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Milde-Langosch K: The Fos family of
transcription factors and their role in tumourigenesis. Eur J
Cancer. 41:2449–2461. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee AV, Cui X and Oesterreich S:
Cross-talk among estrogen receptor, epidermal growth factor, and
insulin-like growth factor signaling in breast cancer. Clin Cancer
Res. 7:4429s–4435s. 2001.
|
|
38
|
Hanstein B, Djahansouzi S, Dall P,
Beckmann M and Bender H: Insights into the molecular biology of the
estrogen receptor define novel therapeutic targets for breast
cancer. Eur J Endocrinol. 150:243–255. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Morishita S, Niwa K, Ichigo S, et al:
Overexpressions of c-fos/jun mRNA and their oncoproteins (Fos/Jun)
in the mouse uterus treated with three natural estrogens. Cancer
Lett. 97:225–231. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Musgrove EA, Lee C and Sutherland RL:
Progestins both stimulate and inhibit breast cancer cell cycle
progression while increasing expression of transforming growth
factor alpha, epidermal growth factor receptor, c-fos, and c-myc
genes. Mol Cell Biol. 11:5032–5043. 1991.PubMed/NCBI
|
|
41
|
Sutherland RL, Prall OW, Watts CK and
Musgrove EA: Estrogen and progestin regulation of cell cycle
progression. J Mammary Gland Biol Neoplasia. 3:63–72. 1998.
View Article : Google Scholar
|
|
42
|
Xing Z, Gauldie J, Cox G, Baumann H,
Jordana M, Lei XF and Achong MK: IL-6 is an antiinflammatory
cytokine required for controlling local or systemic acute
infammatory responses. J Clin Invest. 101:311–320. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
He G, Dhar D, Nakagawa H, et al:
Identification of liver cancer progenitors whose malignant
progression depends on autocrine IL-6 signaling. Cell. 155:384–396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Seifart C, Plagens A, Dempfle A, et al:
TNF-α, TNF-β, IL-6, and IL-10 polymorphisms in patients with lung
cancer. Dis Markers. 21:157–165. 2013. View Article : Google Scholar
|
|
45
|
Hartman ZC, Poage GM, Den Hollander P, et
al: Growth of triple-negative breast cancer cells relies upon
coordinate autocrine expression of the proinflammatory cytokines
IL-6 and IL-8. Cancer Res. 73:3470–3480. 2013. View Article : Google Scholar : PubMed/NCBI
|
